This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gilmartin, R. Articles by Nadell, J. Search for Related Content PubMed PubMed Citation Articles by Gilmartin, R. Articles by Nadell, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cerebral Palsy Social Bookmarking                         What's this?

Intrathecal Baclofen for Management of Spastic Cerebral Palsy: Multicenter Trial

HCA/Wesley Medical Center, Neurology Center of Wichita Wichita, KS

Derek Bruce, MD

Medical City Dallas Hospital Dallas, TX

Bruce B. Storrs, MD

Medical University of South Carolina Charleston, SC

Rick Abbott, MD

New York Medical Center, Division of Pediatric Neurosurgery New York, NY

Linda Krach, MD

Gillette Children's Hospital St Paul, MN

John Ward, MD

Medical College of Virginia Richmond, VA

Karen Bloom, MD

Frazier Rehabilitation Center Louisville, KY

William H. Brooks, MD

Good Samaritan Hospital, Neurological Associates Lexington, KY

Dennis L. Johnson, MD

Hershey Medical Center, Division of Neurosurgery Hershey, PA

Joseph R. Madsen, MD

Children's Hospital of Boston dsen), Boston, MA

John F. McLaughlin, MD

Children's Hospital and Medical Center Seattle, WA

Joseph Nadell, MD

Children's Hospital New Orleans, LA

Intrathecal baclofen infusion has demonstrated effectiveness in decreasing spasticity of spinal origin. Oral antispasticity medication is minimally effective or not well tolerated in cerebral palsy. This study assessed the effectiveness of intrathecal baclofen in reducing spasticity in cerebral palsy. Candidates were screened by randomized, double-blind, intrathecal injections of baclofen and placebo. Responders were defined as those who experienced an average reduction of 1.0 in the lower extremities on the Ashworth Scale for spasticity. Responders received intrathecal baclofen via the SynchroMed System and were followed for up to 43 months. Fifty-one patients completed screening and 44 entered open-label trials. Lower-extremity spasticity decreased from an average baseline score of 3.64 to 1.90 at 39 months. A decrease in upper-extremity spasticity was evidenced over the same study period. Forty-two patients reported adverse events. Most common reports were hypotonia, seizures (no new onset), somnolence, and nausea or vomiting. Fifty-nine percent of the patients experienced procedural or system-related events. Spasticity in patients with cerebral palsy can be treated effectively by continuous intrathecal baclofen. Adverse events, although common, were manageable. (J Child Neurol 2000;15:71-77).

Journal of Child Neurology, Vol. 15, No. 2, 71-77 (2000)
DOI: 10.1177/088307380001500201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. de Lissovoy, L. S. Matza, H. Green, M. Werner, and T. Edgar Cost-effectiveness of Intrathecal Baclofen Therapy for the Treatment of Severe Spasticity Associated With Cerebral Palsy J Child Neurol, January 1, 2007; 22(1): 49 - 59. [Abstract] [PDF]

				D. L. Hurst, W. A. Lajara-Nanson, and M. E. Lance-Fish Walking With Modafinil and Its Use in Diplegic Cerebral Palsy: Retrospective Review J Child Neurol, April 1, 2006; 21(4): 294 - 298. [Abstract] [PDF]

				D. Hurst and N. Cedrone Modafinil for Drooling in Cerebral Palsy J Child Neurol, February 1, 2006; 21(2): 112 - 114. [Abstract] [PDF]

				D. L. Hurst, W. A. Lajara-Nanson, P. Dinakar, and R. B. Schiffer Retrospective Review of Modafinil Use for Cerebral Palsy J Child Neurol, December 1, 2004; 19(12): 948 - 951. [Abstract] [PDF]

				W. C. Cooley and and Committee on Children with Disabilities Providing a Primary Care Medical Home for Children and Youth With Cerebral Palsy Pediatrics, October 1, 2004; 114(4): 1106 - 1113. [Abstract] [Full Text] [PDF]

				Y. Awaad, H. Tayem, S. Munoz, S. Ham, A. M. Michon, and R. Awaad Functional Assessment Following Intrathecal Baclofen Therapy in Children With Spastic Cerebral Palsy J Child Neurol, January 1, 2003; 18(1): 26 - 34. [Abstract] [PDF]

				A. L. Albright Neurosurgical Treatment of Spasticity and Other Pediatric Movement Disorders J Child Neurol, January 1, 2003; 18(1_suppl): S67 - S78. [Abstract] [PDF]

				J. H. Piatt Jr Treatment of Dystonia in Children AAP Grand Rounds, April 1, 2002; 7(4): 40 - 41. [Full Text] [PDF]

				D. L. Hurst and W. Lajara-Nanson Use of Modafinil in Spastic Cerebral Palsy J Child Neurol, March 1, 2002; 17(3): 169 - 172. [Abstract] [PDF]

				E. M. Goldstein Spasticity Management: An Overview J Child Neurol, January 1, 2001; 16(1): 16 - 23. [Abstract] [PDF]

				L. E. Krach Pharmacotherapy of Spasticity: Oral Medications and Intrathecal Baclofen J Child Neurol, January 1, 2001; 16(1): 31 - 36. [Abstract] [PDF]